TRANS GENIC GROUP INC. (2342) Balance sheet

Market cap

¥3.6B

P/E ratio

23.8x

Transgenics Group supports drug development through specialized lab services like genetically modified mice production and pharmaceutical testing, while also providing business consulting and importing various products from electrical equipment to tableware.

Summary Financials Dividends History Segments Ownership Workforce

Income statement Balance sheet Cash flow Other

	2014/03	2015/03	2016/03	2017/03	2018/03	2019/03	2020/03	2021/03	2022/03	2023/03	2024/03	2025/03	2026/03
Cash and cash equivalents	-	946	1,054	1,059	1,773	1,278	1,603	3,030	4,619	3,459	2,478	2,555	2,135
Marketable securities, current	-	400	-	-	-	-	200	-	6	-	-	-	-
Accounts receivable, net	-	451	488	417	625	694	1,021	1,139	894	1,083	1,343	1,195	1,115
Inventories	-	1	2	5	254	247	712	688	1,024	1,353	1,593	1,349	1,574
Total current assets	-	1,934	1,719	1,697	3,072	2,903	4,334	5,812	7,710	7,562	6,550	6,699	6,709
Property, plant and equipment, net	-	1,407	1,429	1,476	1,509	2,162	2,070	2,125	1,993	1,992	2,142	2,055	1,992
Marketable securities, non-current	-	10	552	515	668	565	313	163	110	106	129	108	224
Total non-current assets	-	1,640	2,186	2,205	2,862	3,572	3,238	3,107	2,731	3,111	3,261	2,888	3,027
Total assets	-	3,574	3,905	3,902	5,935	6,475	7,572	8,919	10,441	10,673	9,811	9,586	9,735
Accounts payable	-	-	-	-	-	-	-	-	-	-	276	413	416
Short-term debt	-	-	-	-	-	130	500	100	390	170	448	680	565
Long-term debt, current	-	-	-	-	210	102	171	223	324	478	453	525	462
Total current liabilities	-	424	495	488	856	1,132	2,005	2,165	2,659	2,744	2,434	3,272	3,848
Total non-current liabilities	-	373	341	241	737	457	1,150	1,717	1,145	1,806	1,378	1,458	1,047
Total liabilities	-	796	836	729	1,593	1,589	3,155	3,882	3,804	4,550	3,813	4,730	4,896
Retained earnings	-	-83	-68	12	33	236	-205	843	2,658	2,147	2,067	928	850
Stockholders' equity	2,765	2,777	3,070	3,173	4,342	4,887	4,417	5,037	6,637	6,123	5,998	4,856	4,839
Working capital	-	-	-	-	-	-	-	-	-	-